Financial Performance - BioHarvest Sciences Inc. reported a quarterly loss of $0.15 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.11, and compared to a loss of $0.04 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $8.52 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 2.91%, while year-ago revenues were $6.03 million, showing growth but still falling short of expectations [2] - Over the last four quarters, the company has surpassed consensus EPS estimates only once, indicating challenges in meeting market expectations [2] Stock Performance - BioHarvest Sciences Inc. shares have increased approximately 41.8% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.6% [3] - The current Zacks Rank for the stock is 3 (Hold), suggesting that shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $10.78 million, and for the current fiscal year, it is -$0.32 on revenues of $40.4 million, indicating ongoing challenges [7] - The outlook for the Medical - Biomedical and Genetics industry, where BioHarvest operates, is currently in the bottom 41% of Zacks industries, which may negatively impact stock performance [8]
BioHarvest Sciences Inc. (BHST) Reports Q2 Loss, Misses Revenue Estimates